eVTE (Electronic Venous Thromboembolism): A Cluster, Randomized, Step-wedge Type II Hybrid Study of an Alert Recommending Extended Duration Thromboprophylaxis for At-risk Discharging Medical Patients to Prevent VTE.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 110
Healthy Volunteers: f
View:

• Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:

‣ Physician, nurse practitioner, or physician assistant hospitalist

⁃ Physician internal medicine

⁃ Physician family medicine

• Patient age ≥ 18 years.

• The encounter must be inpatient.

• A signed hospital discharge order must be present.

• eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met

Locations
United States
Utah
Intermountain Medical Center
RECRUITING
Murray
Contact Information
Primary
Valerie Aston, MBA
valerie.aston@imail.org
801-507-4606
Backup
Carlos Barbagelata, MS
carlos.barbagelata@imail.org
801-507-4607
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2025-09-30
Participants
Target number of participants: 152000
Treatments
Experimental: At-risk patients for which an alert is sent during the intervention phase
Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), thereby meeting criteria for alerting during the intervention phase
Active_comparator: At-risk patients during the baseline phase
Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), and who meet criteria for alerting, but for whom no alert is sent during the baseline phase
Sponsors
Collaborators: Janssen Pharmaceuticals
Leads: Scott C. Woller, MD

This content was sourced from clinicaltrials.gov